ReviewTherapeutic advances in chronic disease2023
Fractional nitric oxide measurement in exhaled air (FeNO): perspectives in the management of respiratory diseases.
Review in Therapeutic advances in chronic disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07606898 (Fractional Exhaled Nitric Oxide as Possible Non - Invasive Biomarker to Assess Obstructive Sleep Apnea Severity), which is not on this map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Fractional Exhaled Nitric Oxide as Possible Non - Invasive Biomarker to Assess Obstructive Sleep Apnea Severity
Who cites it
29 citing papers in PubMed, 43 citations in OpenAlex.
- Effect of Chewing Gum on Fractional Exhaled Nitric Oxide Values in Patients with Asthma: A Proof of Concept Study.Journal of asthma and allergy · 2026Trial
- Impacts of subway air particles on healthy adults: a randomized controlled trial in a Chinese city.Particle and fibre toxicology · 2025Trial
- Acute health effects of ambient air pollution including ultrafine particles in a semi-experimental setting in young, healthy individuals.Particle and fibre toxicology · 2025Trial
- [Efficacy and safety of dust mite subcutaneous immunotherapy in children with allergic asthma： a prospective randomized controlled study].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2024Trial
- Unlocking the potential of bronchoalveolar lavage: a promising supplement therapy for moderate-to-severe allergic asthma.BMC pulmonary medicine · 2026Article
- Treatment response and determinants of asthma control in Eastern Africa.BMC pulmonary medicine · 2026Article
- Associations Between Different Eosinophil Activity Markers and Clinical Outcomes in Young Asthmatics.Clinical and translational allergy · 2026Article
- The Evolving Landscape of COPD Typization.Medicina (Kaunas, Lithuania) · 2026Review
- Type 2 Inflammation in Asthma and COPD: Biomarkers, Clinical Applications, and Targeted Therapies.Journal of inflammation research · 2026Review
- Chronic Obstructive Pulmonary Disease in Never-Smokers-A Distinct Entity Within the COPD Spectrum.Life (Basel, Switzerland) · 2025Review
- Molecular profiling of exhaled breath condensate in respiratory diseases.Annals of medicine · 2025Review
- Clinical, radiological, and laboratory assessment of pulmonary eosinophilia syndrome: a case control study in Saudi Arabia.BMC pulmonary medicine · 2025Article
- From Prognostic Marker to Therapeutic Agent: The Role of Nitric Oxide in Lung Cancer.Journal of clinical medicine · 2025Review
- The Relationship Between Contraceptive Use and Respiratory Function in Women: A Systematic Review.Healthcare (Basel, Switzerland) · 2025Review
- Dupilumab efficacy in patients with type 2 asthma and early Feno level reductions.The journal of allergy and clinical immunology. Global · 2025Article
- Unveiling the Complexities of Pediatric Asthma Treatment: Evidence, Controversies, and Emerging Approaches.Paediatric drugs · 2025Review
- Application of Impulse Oscillometry Combined with Fractional Exhaled Nitric Oxide in Monitoring Asthma Control Levels in Children.Journal of asthma and allergy · 2025Article
- Biological pathways and mechanisms linking COPD and cardiovascular disease.Therapeutic advances in chronic disease · 2025Review
- Association and risk factors analysis of FeNO and CRP in bronchial asthma combined with obstructive sleep apnea.Frontiers in medicine · 2025Review
- The energy-health-environment nexus: assessing the transboundary impacts of coal-fired power plants.Frontiers in public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Exhaled nitric oxide (NO) production, upregulated by inflammatory cytokines and mediators in central and peripheral airways, can be easily and non-invasively detected in exhaled air in asthma and other respiratory conditions as a promising tool for disease monitoring. The American Thoracic Society and European Respiratory Society released recommendations that standardize the measurement of the fractional exhaled NO (FeNO). In asthma, increased FeNO reflects eosinophilic-mediated inflammatory pathways and, as a biomarker of T2 inflammation can be used to identify asthma T2 phenotype. In this setting its measurement has shown to be an important tool especially in the diagnostic process, in the assessment and evaluation of poor adherence or predicting positive response to inhaled corticosteroids treatment, in phenotyping severe asthma patients and as a biomarker to predict the response to biologic treatments. The discovery of the role of NO in the pathogenesis of different diseases affecting the airways and the possibility to estimate the predominant site of increased NO production has provided new insight on its regulatory role in the airways, making it suitable for a potential extended use in clinical practice for different pulmonary diseases, even though its role remains less clear than in asthma. Monitoring FeNO in pulmonary obstructive lung diseases including chronic bronchitis and emphysema, interstitial lung diseases, obstructive sleep apnea and other pulmonary diseases is still under debate but has opened up a window to the role NO may play in the management of these diseases. The use of FeNO is reliable, cost effective and recommendable in both adults and children, and should be implemented in the management of patients with asthma and other respiratory conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.